Latest / Pharmacy Podcast Network / Pharmacogenomics in Pharmacy: How Dr. Josiah Allen is Leading the Future of Precision Medicine | PharmXcel Podcast
Transcript
- 0:07Speaker 1: Thanks for listening to the Pharmacy Podcast Network.
- 0:20Speaker 2: Hello pharmacists.
- 0:21Speaker 3: I'm Katrina Aser, a busy mom, pharmacist, board member, writer,
- 0:25Speaker 3: podcaster and CEO of the Australasian Position Medias and Academy,
- 0:29Speaker 3: where I teach pharmacists and doctors how to bring pharmacogenomics.
- 0:33Speaker 2: To their practices.
- 0:34Speaker 3: But you know what, it wasn't that long ago that
- 0:37Speaker 3: I lack the confidence and clarity to focus on growing
- 0:40Speaker 3: my pharmacy career.
- 0:42Speaker 2: Fast forward a few years.
- 0:43Speaker 3: And many failed attempts, and you'll see the pharmacy career
- 0:46Speaker 3: I have today, one that gives me more freedom and
- 0:49Speaker 3: fulfillment than I ever thought possible, one that only existed
- 0:53Speaker 3: in my day dreams. So I created the Pharming Cell
- 0:56Speaker 3: podcast to help give you, my dear pharmacist friends, simple
- 1:00Speaker 3: and actionable insights to excel in your pharmacy career too.
- 1:04Speaker 3: Insights that are not only clinically irrelevant, but that will
- 1:07Speaker 3: grow your mindset and help you see past the full
- 1:10Speaker 3: walls of the status cule of pharmacy practice. So if
- 1:13Speaker 3: you're an ambitious pharmacist who's ready to exige your pharmacy career,
- 1:17Speaker 3: you're in the right place. Friend. Let's get started.
- 1:31Speaker 4: Globally, the incidents of medication the first drug reactions is
- 1:34Speaker 4: estimating the three to six percent of possible admissions, with
- 1:38Speaker 4: a significant portion of pase occurring in low and middle
- 1:40Speaker 4: income countries were unsafe clear contributes to a high number
- 1:45Speaker 4: at first drug events, potentially reaching one hundred and thirty
- 1:48Speaker 4: four million annually in resulting in two princess million t
- 1:53Speaker 4: study suggests that between two and a half percent in
- 1:55Speaker 4: ten point six percent of possible admissions in Europe are
- 1:58Speaker 4: due to adverse drug reaction, while in the United States
- 2:01Speaker 4: it's estimated a three sis percent, but due to underreporting,
- 2:05Speaker 4: the true accidents often freeze drug reactions is likely to
- 2:07Speaker 4: be higher than reported statistics.
- 2:10Speaker 2: The fact that it is learned to be the fourt
- 2:11Speaker 2: leading cause of these in the United States.
- 2:13Speaker 4: That's just like Quolypharmacy medication interactions all to Asia among
- 2:17Speaker 4: disposed and contribute to this but an often overlooked.
- 2:20Speaker 2: Factor as ephi's genetics.
- 2:22Speaker 4: As pharmacists with are medication expertise, we are uniquely positioned
- 2:26Speaker 4: to be used for as drug reactions and enhance medication safety.
- 2:29Speaker 2: With the tools such as pharmacogonomics.
- 2:32Speaker 4: A field that tables drug therapy based on individual's photic.
- 2:35Speaker 5: Profile, powerful tool to.
- 2:37Speaker 2: Optimize treatment and minimize harm.
- 2:40Speaker 4: Pharmacists are the medication experts at the forefront of patient
- 2:44Speaker 4: hear bridging the gap between pharma pushmics and its practical application.
- 2:48Speaker 4: By integrating pharma posomics into clinical practice, we can personalize
- 2:52Speaker 4: the therapy, reduce droll and error, persprobity, and ultimately.
- 2:56Speaker 2: Improve patient outcomes.
- 2:58Speaker 4: But work does it change adopts inflical pharmacy practice. How
- 3:02Speaker 4: can we need yougate this implementation and what skills do
- 3:05Speaker 4: we need to drive this transformation health Here join me
- 3:08Speaker 4: today for an amazing discussion with my keys.
- 3:11Speaker 3: Hello everybody, welcome to another episode of the Farm Mix
- 3:14Speaker 3: Out podcast. Today, I'm joined by two experts who are
- 3:17Speaker 3: actively shaping the future of precision medicine and pharmacy practus.
- 3:21Speaker 3: They'll share insights on how pharmacists can embrace this field,
- 3:24Speaker 3: overcome barriers, and become champions of precision medicine in their communities.
- 3:28Speaker 3: Pharmacolomics is not mystique or sci fi. This is something
- 3:32Speaker 3: that is happening and we need you on board. So
- 3:34Speaker 3: please stay with us through this podcast and we'll share
- 3:36Speaker 3: some valuable insights. Let us, welcome our guests for today.
- 3:40Speaker 3: I'll hand over to Christine. Christine, let us not about yourself.
- 3:44Speaker 1: Sure, I'm Christine Ashcraft. I have now been in pharmacoe
- 3:48Speaker 1: genomics for twenty five years, started by four in two
- 3:51Speaker 1: thousand and one of the first clear credited labs to
- 3:55Speaker 1: offer testing in the country.
- 3:56Speaker 5: And it's long past time that this is standard of care.
- 4:00Speaker 3: Absolutely, And then we hand over to Briens.
- 4:03Speaker 2: Let us know what you're all about, sure.
- 4:06Speaker 6: Doctor Burns Blacksaw.
- 4:08Speaker 7: My first exposure to pharmacogenomics was in the mid nineties
- 4:12Speaker 7: during my PhD training when we found one of the
- 4:17Speaker 7: early genetic mutations that meant people failed a clinical trial
- 4:21Speaker 7: for a beta blocker. And I've been using genetics to
- 4:27Speaker 7: identify novel diagnostics therapeutics ever since. Really passionate about implementing
- 4:33Speaker 7: precision medicine in health systems and with providers, and really
- 4:39Speaker 7: key to our podcast today is democratizing pharmacogonomics for all,
- 4:44Speaker 7: because I think that's the goal.
- 4:46Speaker 3: Brilliant So Brins, I am a pharmacist and I have
- 4:50Speaker 3: no idea what this big long word means. Can you
- 4:52Speaker 3: tell me a little bit about it and why it
- 4:54Speaker 3: is important? Right?
- 4:55Speaker 7: Now, yeah, absolutely, it's a great question. Quite often we
- 5:01Speaker 7: get scared when we hear words we don't know because
- 5:03Speaker 7: we think we're smart pharmacists or pharmacologists like myself, for
- 5:08Speaker 7: you know, physicians providers. Pharmacogenomics sounds really big, but it
- 5:12Speaker 7: really just means making sure that your DNA matches your medications.
- 5:19Speaker 6: So I think a.
- 5:21Speaker 7: Really sobering fact is that in the United States, for example,
- 5:25Speaker 7: the fourth leading cause of death after cardiovaster disease, cancer,
- 5:31Speaker 7: and stroke is actually adverse drug events. So our intent
- 5:36Speaker 7: to treat is often sadly a cause of death if
- 5:40Speaker 7: we don't pay attention to the way that not only
- 5:42Speaker 7: drugs interact with each other, but how they interact with
- 5:45Speaker 7: our genes. And as a patient receives a pharmacogenomic test
- 5:50Speaker 7: and a pharmacist, we believe pharmacists should be central to
- 5:54Speaker 7: this optimizes not only the drug drug but the drug
- 5:58Speaker 7: gene interactions. We can really optimized outcomes. And we may
- 6:01Speaker 7: have a chance to talk later in the podcast about
- 6:03Speaker 7: a number of publications that we and others have had
- 6:06Speaker 7: showing that it can truly not only optimize outcomes, reduce.
- 6:10Speaker 6: Their visits hospitalizations, would also.
- 6:12Speaker 3: Reduce cost of care absolutely, And Christaine, tell me what
- 6:16Speaker 3: is the biggest myth you hear pharmacists or health practitioners
- 6:20Speaker 3: say about pharmacogenomics that holds back people from implementing this
- 6:25Speaker 3: in practice.
- 6:26Speaker 1: I think to your point, a lot of people are like, ooh,
- 6:28Speaker 1: big scary word.
- 6:30Speaker 5: I don't have the training or understanding. I didn't learn
- 6:33Speaker 5: about this.
- 6:33Speaker 1: And I would say, if people have an understanding of
- 6:37Speaker 1: drug drug interactions, then they intuitively understand drug gene interactions.
- 6:43Speaker 1: The FDA and Drug Development Guidance for decades provided a
- 6:47Speaker 1: list of drugs to make a patient as if they
- 6:50Speaker 1: were a poor metabolizer or an ultra rapid metabolizer. You
- 6:54Speaker 1: may remember from pharmacy school inhibitors and inducers.
- 6:58Speaker 5: Either potent or.
- 7:01Speaker 1: And having pharmacogenetic variations or essentially like having inhibitors or
- 7:08Speaker 1: inducers that can never go away. This is a very simple,
- 7:13Speaker 1: natural extension of what we do.
- 7:15Speaker 5: And I think.
- 7:15Speaker 1: Sometimes people get bogged down in the star one star
- 7:19Speaker 1: forard cytochrome being four of fifty twenty six, Like, sure,
- 7:23Speaker 1: there's a lot of terminology, but at the end of
- 7:25Speaker 1: the day, I like to, you know, maybe slightly oversimplify it,
- 7:29Speaker 1: but we are pretending everybody has two lanes of mainly
- 7:33Speaker 1: these cytochrome highways that process medications, when genetically some of
- 7:37Speaker 1: us have one lane, three lanes, or no lane at all,
- 7:43Speaker 1: and having that information really helps us optimize drug indo selection.
- 7:48Speaker 3: That's such a great way of putting it, because a
- 7:50Speaker 3: lot of pharmacists do get overwhelmed by that, and I
- 7:52Speaker 3: think they I think a lot of pharmacists don't know that. Actually,
- 7:57Speaker 3: you know, labs like xs DX and other labs, they
- 8:01Speaker 3: actually tell you pretty much what to do on the report,
- 8:04Speaker 3: so you don't actually need need to do much in
- 8:07Speaker 3: the way of thinking, oh, what do I do now.
- 8:09Speaker 3: It's more about combining your knowledge of pharmacology drug interactions
- 8:13Speaker 3: and bringing in that you need to components.
- 8:16Speaker 2: So it's just.
- 8:16Speaker 3: Another bio marker really that we can use to optimize
- 8:20Speaker 3: medication outcomes. So yes, it might come across as a massive, big,
- 8:24Speaker 3: long word, but it is just business as usual when
- 8:28Speaker 3: I when you try to implement it and.
- 8:30Speaker 2: Practice, it's just business as usual.
- 8:31Speaker 3: So it's not anything that a common job blogs.
- 8:34Speaker 2: Pharmacist wouldn't know what to do.
- 8:36Speaker 3: Some really, you know, it's a great way to put
- 8:39Speaker 3: to put it and explain it that way that it's
- 8:41Speaker 3: a lot less overwhelming that what it seems so brings
- 8:44Speaker 3: back to you. You've completed a number of publications that
- 8:48Speaker 3: shows that PGX can optimize patient care and medication outcomes.
- 8:51Speaker 3: Can you highlight a few of those publications that you've
- 8:53Speaker 3: mentioned and the main takeaway messages.
- 8:57Speaker 6: Sure.
- 8:58Speaker 7: So I've had the pleasure of publishing a number with Christine,
- 9:03Speaker 7: and one that I'll highlight just for people's reference is
- 9:06Speaker 7: a publication we had a couple of years ago that
- 9:08Speaker 7: actually talked about implementing PGX into a health practice, So
- 9:13Speaker 7: I'll refer people to that one. But some prior studies
- 9:17Speaker 7: from Christine and others in our group and then groups
- 9:21Speaker 7: across the world have demonstrated all sorts of positive impacts.
- 9:27Speaker 7: So the recent Prepare trial from Europe in seven thousand
- 9:31Speaker 7: patients demonstrated that a twelve gene pharmacogenetic panel that had
- 9:36Speaker 7: some decisions support along with it so it didn't become
- 9:39Speaker 7: overwhelming for anybody could reduce adverse drug events by thirty
- 9:45Speaker 7: percent over the course of twelve weeks. And in prior
- 9:49Speaker 7: work in a four month study in sixty five and
- 9:57Speaker 7: older medicare population, demonstrated that by using pharmacogenomics plus a
- 10:04Speaker 7: robust clinical.
- 10:05Speaker 6: Decisions support tool could reduce.
- 10:08Speaker 7: Er visits and hospitalizations somewhere from thirty to seventy percent.
- 10:15Speaker 6: And there was an in home study done as well.
- 10:18Speaker 7: Where it showed that it could reduce again er visits, hospitalizations,
- 10:23Speaker 7: and even cost of care quite dramatically. So in the
- 10:26Speaker 7: study I was mentioning before cost of care was reduced
- 10:29Speaker 7: over one thousand dollars in these really acute patients within
- 10:33Speaker 7: home pharmacist physicist was somewhere in the realm of four
- 10:37Speaker 7: thousand dollars in just sixty days in savings plus optimizing outcomes.
- 10:43Speaker 6: So there were a lot of studies. They're not just
- 10:45Speaker 6: stars there from other groups.
- 10:49Speaker 7: Demonstrating a really robust impact on optimizing health outcomes and
- 10:54Speaker 7: reducing cost of care. We already know from other work
- 10:59Speaker 7: done in pharmacy obviously that de prescribing can be very helpful.
- 11:05Speaker 7: I'm sure all of us, if listening, if we've done
- 11:08Speaker 7: anything with care of patients in their medication lists, know
- 11:12Speaker 7: that it's not uncommon to see a patient who has
- 11:14Speaker 7: thirteen twenty medications prescribed by eight to.
- 11:18Speaker 6: Ten different providers.
- 11:19Speaker 7: And again this is where we believe that pharmacists are
- 11:22Speaker 7: really key, is that central nexus of optimizing medication management
- 11:28Speaker 7: using drug drug as well as drug genie interactions to
- 11:32Speaker 7: optimize care across the care team.
- 11:34Speaker 3: And you've worked with a group of pharmacists at Christ's Hospital,
- 11:38Speaker 3: I believe, and you're going to tell us all about
- 11:40Speaker 3: that project and execut stiffs of how you did that.
- 11:43Speaker 3: The other pharmat can do it too inside the elevaterx
- 11:47Speaker 3: dot Live summit, so people who join us and I'm
- 11:50Speaker 3: going to put a link to that in the podcast
- 11:53Speaker 3: notes or those interested in pursuing pharmacogenomics in their practice.
- 11:58Speaker 3: But yes, you're absolutely correct and that there is a
- 12:02Speaker 3: lot of evidence, There is a lot of rasearch. We
- 12:05Speaker 3: do have the backup that brings me to the challenges.
- 12:08Speaker 3: Do you think, either of you, is this purely just
- 12:11Speaker 3: a re case of this is not reimbursed or what
- 12:14Speaker 3: do you think are the.
- 12:14Speaker 2: Real barriers here?
- 12:16Speaker 3: I believe obviously awareness and education is one big barrier,
- 12:19Speaker 3: and this is exactly why we had the Elevator x
- 12:21Speaker 3: sam Acotroonomics Summitch coming up on April twelfth, twelve pm.
- 12:25Speaker 2: To six pm. But what else where is the problem.
- 12:29Speaker 5: Yeah, there.
- 12:31Speaker 1: I think it's a multi pronged problem, like many problems are.
- 12:35Speaker 5: So reimbursement is an issue.
- 12:38Speaker 1: But Medicare in the States has covered pharmacogenetic testing aligned
- 12:42Speaker 1: with CPICK and FDA guidance since twenty twenty thanks to
- 12:45Speaker 1: biomarker legislation. Commercial and Medicaid has followed suit with that
- 12:50Speaker 1: coverage in twenty states and growing, so that's starting to
- 12:53Speaker 1: be addressed.
- 12:53Speaker 5: You also have the education issue.
- 12:55Speaker 1: Ideally we get the Right Drug Does Now Act reintroduced
- 12:59Speaker 1: again this year and actually passed. Please assure congressional representatives
- 13:04Speaker 1: to co sponsor reintroduction of this bill. But it would
- 13:08Speaker 1: invest in healthcare provider education across the board because most
- 13:12Speaker 1: people do not know what a big problem adverse drug
- 13:14Speaker 1: events are and how big of a piece pharmacogenomics can
- 13:18Speaker 1: play in reducing patient harm and reducing healthcare spend. So
- 13:23Speaker 1: spreading the word both to patients and providers is key.
- 13:26Speaker 1: The other thing, though, is technology. I have been involved
- 13:30Speaker 1: in uscript, clinical decision support and some iteration a very
- 13:34Speaker 1: long time, and that came about because I used to
- 13:37Speaker 1: be in charge of sales and marketing for one of
- 13:40Speaker 1: the first labs to offer testing and of course our
- 13:43Speaker 1: providers will.
- 13:44Speaker 5: Be like, well, how do I know who to test?
- 13:45Speaker 5: How do I know how to act on that?
- 13:48Speaker 1: And integrating something in the clinical workflow that says, hey
- 13:51Speaker 1: test this patient.
- 13:52Speaker 5: It would be helpful.
- 13:54Speaker 1: Hey, this is how you very quickly find another drug
- 13:57Speaker 1: that would be more appropriate to them or understand and
- 14:00Speaker 1: how do they adjust the dose. It's great to you know,
- 14:03Speaker 1: have reports or drive people to clinical decisions support in
- 14:07Speaker 1: an ordering portal that they can access through the lab.
- 14:11Speaker 1: But the ideal thing is to put it in the workflow.
- 14:13Speaker 1: And that's another thing that the right drug.
- 14:15Speaker 5: Dose now out would do.
- 14:16Speaker 1: Hit the easy button, make it easy for people to
- 14:19Speaker 1: leverage tools that can help us improve patient safety and care.
- 14:23Speaker 2: Absolutely, that is a major barrier.
- 14:25Speaker 3: And I think you know, when you combine all those
- 14:27Speaker 3: vectors together, you know, the lack of workflow integration, and
- 14:31Speaker 3: then combine with the lack of awareness and then the
- 14:34Speaker 3: perceived reimbursement challenges some of them are real in some states.
- 14:40Speaker 3: You then you really hit a hit a something blok
- 14:43Speaker 3: and you think, okay, this is just too hard. I'll
- 14:45Speaker 3: just take the easy pattern. I'll stick with the status
- 14:47Speaker 3: qule because it's safe and.
- 14:48Speaker 2: I know what I'm doing.
- 14:50Speaker 3: Have you any of you ever, you know, approached universities
- 14:55Speaker 3: to understand, like I'm obviously not in the United States,
- 14:58Speaker 3: what is the standard of equasonomics and undergraduo education because
- 15:02Speaker 3: I know that some of them have postgraduate programs.
- 15:04Speaker 2: But I just feel like that's a little bit too late.
- 15:07Speaker 3: You know, you want to kind of embade these principles
- 15:10Speaker 3: earlier on and the educational journey pharmacists and doctors. So
- 15:15Speaker 3: do you have any experience with that or have you
- 15:17Speaker 3: approached universities to tackle this problem in awareness and education? Yeah?
- 15:23Speaker 7: So I still have an adjunct appointment and I'm very
- 15:27Speaker 7: active in education if I could. Before I get to that,
- 15:30Speaker 7: I'm just going to go back to the question that
- 15:33Speaker 7: you asked Christine, and I Christine gave a wonderful answer,
- 15:37Speaker 7: I think from an adoption standpoint.
- 15:40Speaker 6: Another.
- 15:43Speaker 7: Another major hurdle is that, in our opinion, again pharmacists
- 15:50Speaker 7: at the center the core, but also a broad panel test,
- 15:53Speaker 7: you want to make sure that you're testing for all
- 15:56Speaker 7: of the gene drug interactions that you should be looking for.
- 16:00Speaker 7: And then you have the adoption problem from a physician
- 16:03Speaker 7: standpoint of what if the drug that's impacted is not
- 16:09Speaker 7: the one that I'm managing.
- 16:11Speaker 6: What's my liability there?
- 16:13Speaker 7: Yeah, and then that becomes a real sticking point for
- 16:19Speaker 7: for the adoption as well, because they don't want that
- 16:21Speaker 7: liability of managing amitation perceived perceived liability. Thank you, Christine.
- 16:30Speaker 7: So back to the education standpoint, you know, we have
- 16:34Speaker 7: significant challenges because right now pharmacogenomics is not even part
- 16:38Speaker 7: of medical school curricula, and even in pharmacy school it's
- 16:45Speaker 7: a it's a.
- 16:46Speaker 6: Relatively minimal part of most curricula.
- 16:50Speaker 7: So I would love to go back to the you know,
- 16:53Speaker 7: the earlier stages of undergrad education or even high school,
- 16:56Speaker 7: and I do get invited to participate in those on
- 16:59Speaker 7: a regular basis. I would love for the education to
- 17:03Speaker 7: be for everyone, and I would love for it to
- 17:05Speaker 7: start early. But I think right now just having the
- 17:09Speaker 7: efforts of getting it into medical school education so that
- 17:14Speaker 7: when you, as the pharmacist are speaking with the physician
- 17:17Speaker 7: that their training has actually included what you want to
- 17:20Speaker 7: talk about. So I love the idea of education, and
- 17:25Speaker 7: Christine and I and others have all done a lot
- 17:29Speaker 7: of advocacy work and work on this. Right Drug dost
- 17:32Speaker 7: Now Act the Christine has worked on you fervently for
- 17:36Speaker 7: quite some time now. But you know, we have to
- 17:41Speaker 7: start somewhere, and I think that the starting somewhere right
- 17:44Speaker 7: now is making sure that the practitioners, the.
- 17:46Speaker 6: Pharmacists and the physicians.
- 17:49Speaker 7: At least have an understanding, and then maybe it's time
- 17:52Speaker 7: for the public to understand as well.
- 17:54Speaker 6: And we probably haven't done a great.
- 17:56Speaker 7: Job educating the public yet on this big, long word
- 17:59Speaker 7: that connection optimize their healthy.
- 18:02Speaker 1: So we don't talk about it at cocktail parties. Every
- 18:05Speaker 1: time I'm at one, and pretty much everybody I tell
- 18:08Speaker 1: the pharma code, you know, by explaining they're like, oh,
- 18:10Speaker 1: everybody should do this.
- 18:12Speaker 2: I know this.
- 18:13Speaker 3: Is exactly the action you get from every was like,
- 18:15Speaker 3: but why did my doctor not tell me about this?
- 18:19Speaker 3: And then it's a very hard situation because when I
- 18:24Speaker 3: first started Pharmacristynomics and I got that comment, and I
- 18:26Speaker 3: have received that comment from probably ninety percent of my patients, like,
- 18:30Speaker 3: but this is so important?
- 18:31Speaker 2: Why is it not standard of care?
- 18:34Speaker 3: And then you kind of pause and you say, well,
- 18:35Speaker 3: I don't really want to blame it on the south system,
- 18:37Speaker 3: and I don't really want to blame it on the
- 18:38Speaker 3: doctor that they don't don't don't want to blame.
- 18:40Speaker 2: It on anyone. It's like, but and you also don't
- 18:42Speaker 2: want to say there's no evidence.
- 18:44Speaker 3: That's why it's just really early on. So it's a
- 18:47Speaker 3: really that's a really complex question to navigate.
- 18:52Speaker 2: What do you think?
- 18:53Speaker 1: I do think part of the issue is the silos
- 18:57Speaker 1: that patient care is divided in. So I go to
- 19:00Speaker 1: my PCP and then they're like, oh, you're diabetic, go
- 19:02Speaker 1: see an undercronologists.
- 19:03Speaker 3: Don't.
- 19:03Speaker 5: You're depressed, go see a psychiatrist. Do your duda duh. Great.
- 19:06Speaker 1: So now you have all these specialists and they do
- 19:09Speaker 1: different things, and god forbid you get cancer.
- 19:11Speaker 5: Now you have an oncologist.
- 19:13Speaker 1: And so all of these people are prescribing medications. Nobody's
- 19:16Speaker 1: writing proper. Hurt on it right, And then pharmacogenomics impacts
- 19:20Speaker 1: all of these medications and all of these different areas,
- 19:24Speaker 1: and the specialists that can manage that is a pharmacist.
- 19:27Speaker 5: And part of the issue, at least in the US,
- 19:29Speaker 5: is that.
- 19:29Speaker 1: Pharmacists are not federally recognized as healthcare providers, even though
- 19:34Speaker 1: they have just as much education to get a farm
- 19:37Speaker 1: d degree as an MD. Like you go to school
- 19:40Speaker 1: a long time, These should be recognized healthcare providers. Pas
- 19:44Speaker 1: don't go to school that long, nurses don't go to
- 19:46Speaker 1: school that long. Like it doesn't make sense, but those
- 19:51Speaker 1: are the healthcare specialists that should be optimizing medications. I
- 19:56Speaker 1: think of polypharmacy as if it were a disease state,
- 19:59Speaker 1: and we should be fighting it as if it is
- 20:01Speaker 1: the worst disease state we are dealing with, because frankly
- 20:04Speaker 1: it is. Pharmacists should be getting paid to do reviews.
- 20:11Speaker 1: There are paths to do that to optimize these medications,
- 20:15Speaker 1: including incorporating PGX, but I think they can help us
- 20:18Speaker 1: overcome the silos, and that's part of the issue we've
- 20:21Speaker 1: dealt with.
- 20:24Speaker 5: Cross.
- 20:26Speaker 3: Yeah.
- 20:26Speaker 7: I think there's also Katrina a recent study out of
- 20:30Speaker 7: the UK where they are trying to implement panel pharmacogenomic testing.
- 20:38Speaker 7: And this study was really great because they and this
- 20:42Speaker 7: is exactly the same as Christine's experience in cocktail parties
- 20:45Speaker 7: and mine and so many others, is that nobody really
- 20:49Speaker 7: knows what it is, but when people learn what it is,
- 20:52Speaker 7: greater than ninety percent of them would like to do it.
- 20:58Speaker 6: So part of our role is education to drive adoption.
- 21:04Speaker 7: Sometimes the best advocacy is walking into the doctor's office
- 21:07Speaker 7: and saying I want to do this. So it's and
- 21:12Speaker 7: perhaps our best work is to help pharmacists understand this
- 21:18Speaker 7: so that they can work with patients to then convince
- 21:23Speaker 7: practitioners who got no training on this when they trained
- 21:26Speaker 7: twenty years ago, to try to help optimize care across
- 21:30Speaker 7: the care team with the pharmacist at the core.
- 21:32Speaker 2: As Burns.
- 21:33Speaker 1: This came up earlier today and I thought it was
- 21:35Speaker 1: a great point. How when you had embedded pharmacists at
- 21:39Speaker 1: first there was some resistance and then by the end
- 21:42Speaker 1: they were like, you will take I think that the
- 21:45Speaker 1: quote was you will take my pharmacist away over my
- 21:47Speaker 1: cold dead body. But all healthcare providers are burnt out,
- 21:54Speaker 1: like pharmacists can help with this.
- 21:58Speaker 5: Burnout issue. They can come in and.
- 22:00Speaker 1: Help reduce burden and optimize care, and we need to
- 22:05Speaker 1: remove that like this. This behooves everybody. It helps the
- 22:08Speaker 1: healthcare providers, it helps the patients. It doesn't make any
- 22:11Speaker 1: sense that there are barriers to enabling pharmacists to do this.
- 22:15Speaker 2: More broadly, you know.
- 22:17Speaker 3: I think you've hit the nail on the head because
- 22:19Speaker 3: I don't think it is so much like we discussed
- 22:22Speaker 3: the awareness and education pace, but there is the empowerment
- 22:25Speaker 3: piece that pharmacists need and not wishing to promote the
- 22:29Speaker 3: academy that you know that I've put together.
- 22:31Speaker 2: But quarters. So the academy has three parts.
- 22:35Speaker 3: The clinical knowledge which is part one, Part two and
- 22:37Speaker 3: part three are purely business empowerment. This is how you
- 22:41Speaker 3: go out and speak about PGX to the communities. This
- 22:45Speaker 3: is what you say to the doctors. Here is a
- 22:47Speaker 3: presentation with all the data. This is exactly what you
- 22:50Speaker 3: need to say. So it's like and sadly, when you
- 22:53Speaker 3: have been through I don't know, six seven years of university,
- 22:56Speaker 3: you kind of get used to being spoon feed everything.
- 22:59Speaker 3: Like I think this is what pharmacists are kind of
- 23:01Speaker 3: looking for the empowerment phase.
- 23:03Speaker 2: You can actually do this.
- 23:04Speaker 3: This is your expertise, this is within your realm, but
- 23:08Speaker 3: this is.
- 23:08Speaker 2: Also how you do it.
- 23:10Speaker 3: This is steep by Steve, how you approach this, which
- 23:12Speaker 3: is really something that we're trying to do with the
- 23:14Speaker 3: event that we've created. But yeah, like you said, pharmacists
- 23:19Speaker 3: needs need to be empowered to help doctors with burnout.
- 23:25Speaker 3: And I think part of it is also you will
- 23:27Speaker 3: probably come across in pharmacy, there's a lot of tension
- 23:31Speaker 3: between pharmacists and doctors. It's not often something that can
- 23:36Speaker 3: easily be overcome. Like if you can just get in
- 23:38Speaker 3: through the door, that's a huge step. Now you build
- 23:41Speaker 3: that relationship, and I think that's actually really important point
- 23:44Speaker 3: is you don't go attacking them with PGX straight away.
- 23:46Speaker 3: You kind of have to build that relationship showing them
- 23:48Speaker 3: the value of pharmacists, of medicines, reconciliations, of medication reviews
- 23:52Speaker 3: and cements and all that, and then you bring in PGX,
- 23:55Speaker 3: because if you approach it from the start, it's going
- 23:59Speaker 3: to be oh my god, like this is just far
- 24:01Speaker 3: too complicated.
- 24:02Speaker 2: I can't do all of this.
- 24:03Speaker 3: You can't send me a report with three hundred recommendations
- 24:05Speaker 3: on it.
- 24:06Speaker 2: What do I do with this sort of thing?
- 24:09Speaker 7: Yeah, and Katrina, that was we'll talk about it more
- 24:12Speaker 7: during the Elevator summit, but that was exactly our experience.
- 24:17Speaker 7: Our pharmacists were introduced simply for hypertension diabetes medication management
- 24:22Speaker 7: for nearly a year before we introduced the word pharmacosyonomics.
- 24:28Speaker 6: Because you need to build that relationship.
- 24:30Speaker 7: So part of part of the goal is education and
- 24:35Speaker 7: developing the relationship of trust to where the provider doesn't
- 24:41Speaker 7: feel threatened by a pharmacist stepping on their territory. And ultimately,
- 24:49Speaker 7: late Christine mentioned, comes to see the value of the
- 24:52Speaker 7: pharmacist because they can do medic They get five times
- 24:55Speaker 7: the training any physician does in medication management during it
- 24:59Speaker 7: for a residency trained pharmacists, So sooner or later people
- 25:04Speaker 7: providers can appreciate the benefit of that in their practice.
- 25:08Speaker 7: And like Christine and you were both saying, reduce the
- 25:11Speaker 7: burnout that is happening across all clinical care.
- 25:16Speaker 2: Absolutely.
- 25:17Speaker 3: And I'm a pharmacist and I work in a community
- 25:20Speaker 3: pharmacy setting, and I feel like this is far too complex.
- 25:23Speaker 2: To implement in community pharmacy. Well what are your opinions?
- 25:26Speaker 2: What do you think?
- 25:29Speaker 6: Oh boy, that's an.
- 25:30Speaker 1: Interesting drug interaction management and clinical pharmacy. As I said earlier,
- 25:36Speaker 1: it's the same thing. If you can manage drug drug
- 25:39Speaker 1: you can manage drug gene, you can manage multi factor
- 25:42Speaker 1: use script clinical.
- 25:44Speaker 5: Decisions support tool.
- 25:45Speaker 1: We used to have a team a pharmacist and they
- 25:48Speaker 1: created these personalized prescribing reports based on genetic test results
- 25:53Speaker 1: and the medications and herbals and over the counters a
- 25:56Speaker 1: patient was taking things like Beer's criteria smoking, and it
- 26:01Speaker 1: used to take about twenty to thirty minutes on average
- 26:03Speaker 1: for our pharmacists to create these personalized recommendations when patients
- 26:07Speaker 1: were tested. We kept upgrading and improving use script and
- 26:11Speaker 1: automating things, and we brought our time down to two
- 26:14Speaker 1: to three minutes per patient on average, taking almost nine
- 26:18Speaker 1: medications to provide personalized guidance to providers to help optimize
- 26:23Speaker 1: that patient's care. It's so incredibly helpful. Even when you
- 26:28Speaker 1: automate the heck out of things, you still need a
- 26:30Speaker 1: pharmacist to go, hey, we need to change this medication,
- 26:33Speaker 1: or maybe we can stop it. This patient's been on
- 26:35Speaker 1: it for six years, it hasn't done a thing. Why
- 26:37Speaker 1: are they even on it at all?
- 26:38Speaker 5: Stop?
- 26:39Speaker 1: Or hey, we need to find an alternative medication.
- 26:42Speaker 5: These two are the.
- 26:43Speaker 1: Best options, or this one is the best option. That
- 26:46Speaker 1: piece in there. It saves time, it improves care. But
- 26:49Speaker 1: those kinds of tools, they're there to make life easier.
- 26:53Speaker 2: They're useful, absolutely. And let's round it up with the
- 27:01Speaker 2: last question.
- 27:01Speaker 3: If a pharmacist is sitting on the things about attending the.
- 27:05Speaker 2: Elevator Pharmacosonomic Summit. What would you tell them?
- 27:12Speaker 6: We're cool?
- 27:14Speaker 2: Absolutely, you need to join because we're cool.
- 27:19Speaker 6: Yeah, I'm hang out with the cool kids, you know.
- 27:24Speaker 7: I think the simple reality is all of us are educated,
- 27:31Speaker 7: and me and a pharmacist and anyone else. If I
- 27:34Speaker 7: could get paid to continually educate myself.
- 27:40Speaker 6: I would do that. That would be the greatest job ever.
- 27:43Speaker 7: So this is a great opportunity to expand your horizons
- 27:48Speaker 7: and understand that this big word that might seem scary
- 27:53Speaker 7: is really just an extension of what you're already doing
- 27:56Speaker 7: as a pharmacist and can really help optimize the care
- 28:00Speaker 7: that you can provide. And then you know, in partnership
- 28:04Speaker 7: with your academy and others, you can learn how to
- 28:07Speaker 7: implement this. So implementation is probably the last but most
- 28:12Speaker 7: difficult mile or kilometer.
- 28:15Speaker 3: And but you're making it easy, right, You've got x
- 28:17Speaker 3: DX and you scribed all those amazing tools we've just
- 28:20Speaker 3: told about.
- 28:20Speaker 2: It's actually not as hard that we can't implement this.
- 28:25Speaker 3: Yeah.
- 28:26Speaker 7: So I think from my perspective, we are here to
- 28:29Speaker 7: help make big word become easy button.
- 28:32Speaker 1: Absolutely, And to that end, I just shared the pg
- 28:37Speaker 1: X track at PMWC and a pharmacists that implemented at
- 28:45Speaker 1: cancer Center really helped lead the charge there. It was like,
- 28:49Speaker 1: you know, don't let perfection be the enemy of good.
- 28:52Speaker 1: Just get started, and so I will be talking about good, better, best,
- 28:57Speaker 1: Sure best is integrated clinical decision support right in the
- 29:00Speaker 1: pharmacy software system or EHR.
- 29:03Speaker 5: Right, we don't need that.
- 29:04Speaker 1: There are tools we can use that help us do
- 29:07Speaker 1: this for some of our patients when it is most impactful.
- 29:10Speaker 1: And the key is really just to start somewhere, not
- 29:14Speaker 1: to let perfections law you down.
- 29:16Speaker 2: And the reality is that I'm not I don't know.
- 29:18Speaker 3: Maybe you know the answer to this, but I don't
- 29:20Speaker 3: know if a single healthcare system that has all of
- 29:21Speaker 3: that integrated into it anyway, Like even here in New Zealand,
- 29:25Speaker 3: this is like but Wayne cities, we don't have shared records.
- 29:29Speaker 3: So but yeah, it is a challenge. So absolutely, if
- 29:34Speaker 3: you're going to wait for our technology to support this,
- 29:37Speaker 3: it's not never going to happen.
- 29:40Speaker 1: I don't know about New Zealand, but we still fax
- 29:43Speaker 1: things here.
- 29:44Speaker 2: No we don't where.
- 29:46Speaker 3: Gosh, you guys are living in the drateful past.
- 29:51Speaker 2: No we don't.
- 29:52Speaker 3: We've thrown away the facts machines. They don't hardly sell
- 29:55Speaker 3: them anywhere anymore, so perfect. Yeah, but no, I guess
- 30:00Speaker 3: on that note, I just want to share I guess
- 30:02Speaker 3: one of my academy students, and this is probably the
- 30:04Speaker 3: most profound story and probably one that many of pharmacists
- 30:07Speaker 3: will resonate with for our listening to. This is she
- 30:10Speaker 3: bg EX tested a patient who was going to have
- 30:13Speaker 3: their eighth stent and they were so that was her
- 30:18Speaker 3: first patient. They were on like thirteen medications and yeah,
- 30:22Speaker 3: upcoming eighth stent and they were a second to nineteen
- 30:28Speaker 3: or metabolizer and they were on.
- 30:29Speaker 2: Clopudoval so they could have died.
- 30:32Speaker 3: So for those of you listening who don't know, that
- 30:34Speaker 3: means they're not actually converting clopidogal to their active form
- 30:38Speaker 3: and they needed alternative therapy and she recommended that. But
- 30:42Speaker 3: they just came at the right time. And that's probably
- 30:44Speaker 3: one of the most profound stories. You know, how many
- 30:47Speaker 3: stints does one need before they realized something is wrong
- 30:50Speaker 3: and this is not working. So yeah, absolutely would encourage
- 30:55Speaker 3: everybody listening to attend. Thank you guys for being here
- 30:59Speaker 3: for your time. Real shiate it and please come and
- 31:01Speaker 3: join us. Come and join Christine and Burns at the
- 31:03Speaker 3: Elevator EXPERGI Summit. I'll put the link in the show notes.
- 31:07Speaker 3: It's been a pleasure to talk to you both. Thank
- 31:09Speaker 3: you so much for your time.
- 31:11Speaker 6: Thank you always a pleasure.
- 31:13Speaker 3: We've been listening to the Far Mix of podcast. If
- 31:15Speaker 3: you haven't yet, subscribe, rate, and give us a review
- 31:18Speaker 3: of this podcast. Feel free to send us your questions
- 31:20Speaker 3: and comments to discuss on the show and join me
- 31:23Speaker 3: next week for another amazing conversation.
- 31:25Speaker 2: Thank you for listening.